Wilms' tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia

Hematology

Volumn 16, Issue 1, 2011, Pages 37-42

  Spassov, B V ^a   Stoimenov, A S ^a   Balatzenko, G N ^a   Genova, M L ^a   Peichev, D B ^a   Konstantinov, Spiro M ^b  

^a Specialized Hospital for Active Therapy of Hematological Diseases   (Bulgaria)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Acute myeloid leukemia; FLT3 ITD; Wilms' tumor protein

Indexed keywords

CD135 ANTIGEN; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; MOLECULAR MARKER; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CARCINOGENICITY; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; INTERNAL TANDEM DUPLICATION; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; WESTERN BLOTTING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM REPEAT SEQUENCES; WT1 PROTEINS;

EID: 79551711403     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X12902908411913     Document Type: Article

References (36)

1. Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T. The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. FEBS Lett 1997;409:41-5. (Pubitemid 27248563)
2. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, et al. WT-1 is required for early kidney development. Cell 1993;74:679-91. (Pubitemid 23259748)
3. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995;9:2143-65.
4. MayoMW,Wang CY,Drouin SS, Madrid LV,MarshallAF, Reed JC, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999;18:3990-4003.
5. Hirose M. The role of Wilms' tumor genes. J Med Invest 1999;46:130-40.
6. Reddy JC, Licht JD. The WT1 Wilms' tumor suppressor gene: how much do we really know? Biochim Biophys Acta 1996;1287:1-28.
7. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-9.
8. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994;8:2138-43.
9. Brieger J, Weidmann E, Maurer U, Hoelzer D, Mitrou PS, Bergmann L. The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann Oncol 1995;6:811-6.
10. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-25.
11. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
12. Barragán E, Cervera J, Bolufer P, Ballester S, Martín G, Fernández P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89:926-33.
13. Lyman SD, Jacobsen SE. c-Kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998;91:1101-34.
14. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol 2001;113:1076-7.
15. Agne's F, Shamoon B, Dina C, Rosnet O, Birnbaum D, Galibert F. Genomic structure of the downstream part of the human FLT3 gene: exon/ intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene 1994;145:283-8.
16. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996;10:588-99.
17. LisovskyM, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, et al. FLT3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukaemia cells: regulation of Bcl-2 and Bax. Blood 1996;88:3987-97. (Pubitemid 26383123)
18. Rombouts WJ, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000;14:675-83.
19. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000;111:190-5.
20. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumors. Pathology and genetics of tumors of haemotopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
21. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 2003;17:1521-8.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9. (Pubitemid 17064313)
23. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-28.
24. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, http://www.ncbi.nlm.nih.gov/pubmed?term5%22Sonoda%20Y%22%5BAuthor%5D et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-8.
25. Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F, et al. Significant co-expression of WT1 and MDR1genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 2004;72:45-51.
26. Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed MR, et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993;7:659-70.
27. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, et al. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1993;82:3133-40.
28. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-7.
29. Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 1997;70:518-23. (Pubitemid 27149634)
30. Al-Adnani M, Williams S, Anderson J, Ashworth M, MaloneM, Sebire NJ. Immunohistochemical nuclear positivity for wt1 in childhood acute myeloid leukemia. Fetal Pediatr Pathol 2007;26:193-7. (Pubitemid 350256161)
31. Cilloni D, Gottardi E, de Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-21.
32. Schmid D, HeinzeG, Linnerth B, Tisljar K, Kusec R, Geissler K, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-43.
33. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-80. (Pubitemid 35434129)
34. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9.
35. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research 2001;61:7233-9.
36. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998;91:2961-8.